Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) remained unaffected at $9.23 after the company reported Q1 results.
Earnings per share were up 20.00% over the past year to ($0.72), which might not be comparable to the estimate of ($0.03).
Revenue of $68,661,000 lower by 9.42% year over year, which beat the estimate of $64,820,000.
Earnings guidance hasn't been issued by the company for now.
AMAG Pharmaceuticals hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: May 11, 2020
Time: 08:00 PM ET
Webcast URL: https://edge.media-server.com/mmc/p/ok5yt4pw
Recent Stock Performance
Company's 52-week high was at $13.53
Company's 52-week low was at $4.41
Price action over last quarter: Up 19.25%
AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.